Akura Medical Secures $53 Million Series C Funding for VTE Solutions Development

Akura Medical Secures $53 Million in Series C Financing

In a significant leap forward for venous thromboembolism (VTE) care, Akura Medical has successfully closed a $53 million first close in its Series C financing round. As a company within the renowned Shifamed portfolio, Akura Medical is dedicated to transforming how VTE is treated, which currently ranks as the third leading cause of cardiovascular death in the US. The funds raised will be instrumental in facilitating the development of their pioneering Katana™ Thrombectomy System and NavIQ™ quantification software.

The financing round was not only led by the Qatar Investment Authority (QIA) but also saw active participation from existing investors. One key aspect of this funding will see a portion allocated for the establishment of a joint venture in Qatar, emphasizing Akura's commitment to expanding its footprint and impact in the Middle Eastern healthcare market.

A Focus on Innovation

According to Amr Salahieh, Chair and Acting Chief Executive Officer of Akura Medical, the company's efforts center around introducing a differentiated set of thrombectomy technologies aimed at enhancing procedural precision and improving patient outcomes. The recent unveiling of the NavIQ quantification software marks an essential step towards integrating intelligent, data-driven methodologies into thromboembolic interventions.

With this new financial backing, Akura Medical is poised to accelerate its product development timelines, thereby laying a robust foundation for sustained long-term growth. Salahieh expressed his gratitude for QIA's trust and partnership as the company continues on its mission to redefine the standards of care within the VTE landscape.

The Akura Medical Product Portfolio

At the heart of Akura Medical's offerings is the Katana System, an innovative thrombectomy system engineered to virtually eliminate diverse types of blood clots. This system stands out in its design, which integrates high-velocity saline jets that effectively disintegrate clots irrespective of their physical characteristics, thereby averting potential occlusions in catheters. Moreover, the system is embedded with sensors that relay real-time data regarding pulmonary artery pressure, enabling healthcare providers to assess the effectiveness of the procedure instantaneously.

Accompanying this is the NavIQ software, a cutting-edge tool designed to transform CT angiogram data into a comprehensive 3D representation of the pulmonary vasculature. This 3D model promises to enhance the anatomical visualization of both arteries and clots, ultimately allowing for meticulous pre-procedural planning. Additionally, NavIQ offers vital clot characterization data, assisting healthcare providers in prioritizing appropriate treatment strategies.

The Urgency of Addressing VTE

The urgency of addressing VTE cannot be overstated. VTE is a complex condition characterized by blood clot formation, often originating in the deep veins of the legs, which can lead to critical blockages in the pulmonary arteries. Such complications drastically hinder blood flow to vital organs and necessitate immediate intervention. With Akura Medical's innovative technologies, the potential to save lives and improve treatment modalities is significantly enhanced.

As Akura Medical forges ahead with its mission, the company remains committed to making an impactful difference in patients' lives across the globe. The Katana™ Thrombectomy System and NavIQ™ software represent the pinnacle of medical technology, combining advanced engineering with insightful data analytics to shape the future of VTE management.

About Akura Medical

Akura Medical, headquartered in Los Gatos, California, is a privately held entity within the Shifamed LLC portfolio. This medical technology company is devoted to revolutionizing the approaches to venous thromboembolism (VTE) treatment. The Katana™ Thrombectomy System serves as the cornerstone of their innovative efforts, aiming to elevate the standard of care for pulmonary embolism (PE) treatment. To explore more about Akura Medical's contributions and offerings, visit their website at akuramedical.com.

Note: The Katana System is currently for investigational use only and is not cleared for sale in the USA or any other country.

About Shifamed, LLC

Founded by serial entrepreneur Amr Salahieh, Shifamed operates as a specialized medical innovation hub. The focus here lies in creating original solutions that expedite market entry, mitigate risks, enhance impact, and assure that patients worldwide can lead healthier, longer lives. More information can be found at shifamed.com.